Loews Corp’s Charles River Laboratories CRL Stock Holding History

Loews Corp’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-6,000	Closed	-$648K	–	162
2017 Q3	$648K	Buy	+6,000	New	+$616K	﹤0.01%	94

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Loews Corp's CRL Position: Q4 2017 in Review

Loews Corp sold out of Charles River Laboratories (CRL) in Q4 2017, closing a stake of 6,000 shares — an estimated $648K sold.

Loews Corp first reported a position in CRL in Q3 2017 and held it in 1 quarter. The position peaked at $648K in Q3 2017. 339 funds tracked by Wall St. Rank hold CRL as of Q4 2017.

Loews Corp reported no remaining Charles River Laboratories position as of Q4 2017 after selling out during the quarter.
Loews Corp sold 6,000 Charles River Laboratories shares in Q4 2017, an estimated $648K.
Loews Corp first reported a position in Charles River Laboratories in Q3 2017 and held it in 1 quarter.
Loews Corp's Charles River Laboratories position peaked at $648K in Q3 2017.
339 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2017.

Based on Loews Corp's 13F filing for Q4 2017, filed 13 Feb 2018.